Astellas Pharma Inc. competitive analysis

Explore Astellas Pharma Inc.'s recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 12, 2026
Patent NumberPublication DateTitleTotal Oppositions
Nov 11, 2026Stable Pharmaceutical Composition For Oral Administration1
Jan 7, 2026Formulations Of Enzalutamide14
Jan 10, 2024Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer3
Jan 11, 2023Stable Pharmaceutical Composition For Oral Administration2
Jul 6, 2022Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer3
Dec 30, 2020Controlled Release Pharmaceutical Composition8
Sep 9, 2020Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer1
Nov 14, 2018Novel Fgfr3 Fusion Product2
Jan 24, 2018Controlled Release Pharmaceutical Composition4
Aug 31, 2016Pharmaceutical Composition For Oral Administration1

Latest PTAB cases involving Astellas Pharma Inc.

Discover the latest PTAB cases involving Astellas Pharma Inc., highlighting their recent legal challenges and patent disputes.

Last updated on: Nov 15, 2026
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Astellas Pharma Inc.

IPR2018-00079Oct 16, 2017SAWAI PHARMACEUTICALASTELLAS PHARMAInstitution Denied

Peer Comparison New

IP litigation analysis comparing Astellas Pharma Inc. with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 12, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
ASTELLAS PHARMA - 34 - 1
ALFRED E TIEFENBACHER785 - -
HAMM&WITTKOPP PATENTANWÄLTE PARTMBB96 - - -
MAIWALD PATENTANWALTS177 - - -